Human LXRβ Reporter Assay Kit

SIZE	SKU	PRICE
1 x-96 well format assays	IB00301	—
3 x-32 assays in-96 well format	IB00301-32	—
1 x-384 well format assays	IB00302	—

SIZE	SKU
1 x-96 well format assays	IB00301
3 x-32 assays in-96 well format	IB00301-32
1 x-384 well format assays	IB00302

Add to quote

Specifications
Data
Target Background
Documentation
Overview
Citation
Related Products

Product Description and Product Data

This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Liver X Receptor Beta (LXR). INDIGO’s LXR Beta reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the LXR Beta. In addition to LXR Beta Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human LXR Beta. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot. Kits must be stored at -80C. Do not store in liquid nitrogen. Note: reporter cells cannot be refrozen or maintained in extended culture.

Features

Ready to Use Upon Receipt
Includes All Needed Components
Contains Transfected Reporter Cells
Eliminates Cell Licensing Fees
Clear, Reproducible Results
Consistent Results Lot to Lot

Product Specifications

Target Type		Nuclear Hormone Receptor
Species		Human
Receptor Form		Hybrid
Assay Mode		Agonist, Antagonist
Kit Components		LXRb Reporter Cells Cell Recovery Medium (CRM) Compound Screening Medium (CSM) TO901317, (ref. agonist; in DMSO) Detection Substrate Detection Buffer White, sterile, cell-culture ready assay plate
Shelf Life		6 months
Orthologs Available		Yes
Shipping Requirements		Dry Ice
Storage temperature		-80C

Data

Agonist dose-response analyses. LXRβ Reporter Cells were treated with a dilutions series of the reference agonists T0901317 (provided), APD (Cayman Chem.) or GW3965 (Tocris).

Antagonist dose-response analyses performed by co-treating reporter cells with a fixed (EC80) concentration or TO901317 and varying concentrations of the reference antagonists GSK 2033 or SR 9243 (Tocris). Luminescence was quantified and average relative light units (RLU) and corresponding values of standard deviation (SD) were determined for each treatment concentration (n = 3). Fold-Activation and Z’ values were calculated as described by Zhang, et al. (1999). Non-linear regression and EC50 / IC50 analyses were performed using GraphPad Prism software.

Target Background

Liver X receptor β (LXRβ) is a member of the nuclear receptor family of transcription factors. LXRβ is encoded by the NR1H2 gene (nuclear receptor subfamily 1, group H, member 2). The Liver X receptors (LXRs) were originally identified as orphan members of the nuclear receptor superfamily because their ligands were unknown. Like other receptors in the family, LXRs heterodimerize with the Retinoid X Receptor and bind to specific response elements (LXREs) characterized by direct repeats separated by 4 nucleotides.

These LXRβ Reporter Assay Systems utilize proprietary mammalian cells engineered to express human NR1H2 protein, commonly referred to as LXRβ.

The principle application of this LXRβ assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the human liver x receptor beta.